The bioSimilia initiative brings the benefits of ultra-minute nano-pharmacological substances to alleviate many disease conditions. Biosimilia is a startup by an eminent physician cum researcher Dr Rajesh Shah, MD, who has been working on researching a COVID-19 Nosode called BiosimCovex. We scientifically prepared three variants of the COVID-19 Nosode at the Haffkine Institute in Mumbai and Gujarat University. They have undergone pre-clinical and clinical evaluation. Scientific information and research findings of the COVID-19 Nosode are shared on this website.

Phase 1, Phase 2, and Phase 3 studies with BiosimCovex have shown encouraging results. BiosimCovex has demonstrated protection against COVID-19 infection in humans by triggering antibody production—a breakthrough finding awaiting regulatory approval.